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LETTERS TO THE EDITOR
Ambulatory oxygen: Is the six-minute walk
test the best option?
means having a long, quiet corridor, some clearly visible
objects to mark the ends of the distance to be covered,






























ROxigenoterapia de deambulac¸ão: será o teste
de 6 minutos de marcha a melhor opc¸ão?
Dear Editor,
We have read with great interest the paper recently
published by Vieira et al. in the Portuguese Journal of Pul-
monology about the efﬁcacy and patterns of ambulatory
oxygen usage in a university hospital.1 To determine pat-
terns of ambulatory oxygen (AO) use among patients with
COPD and interstitial lung diseases, the authors have studied
37 consecutive adult patients on AO by liquid O(2) for more
than 3 months. The acute response to O(2) was evaluated
through the standardized 6-minute walk test (6MWT) and the
Borg dyspnoea scale during a O(2) pre-intervention trial. In
relation to the acute response to O(2) there were signiﬁcant
improvements in the distance walked, in resting SatO(2), in
minimal SatO(2), and in percentage of desaturation, inde-
pendently of the diagnosis. However, acute improvement
in 6MWT parameters was not predictive of enhancement
of outdoor activities with AO. AO was used for a mean of
4.1 h/day and surprisingly, patients spent fewer hours per
day away from home after AO treatment. Moreover, 16% of
the patients were not compliant to the prescription, and 54%
mentioned side effects.
The ATS Guideline for the 6MWT2 have established that
the strongest indication for the 6MWT is for measuring the
response to medical interventions in patients with moder-
ate to severe heart or lung disease, as a one-time measure
of functional status of patients, and as a predictor of mor-
bidity and mortality. The number of meters walked has
been accepted as the main variable to be recorded in these
situations.3 The paper from Vieira et al.1 highlights a num-
ber of important problems related to 6MWT that we would
like to consider.
First of all, it is necessary to say that in this Guideline
there is no reference to the role of the 6MWT in the AO pres-
cription. Second, it is very important to take into account
that the 6MWT is not as simple as it may seem. Not every
walk performed in a hospital in the presence of someone
in a white coat is a walk test. In order for the test to be a
valid instrument of measurement, it should strictly conform
to ofﬁcial guidelines, for reasons of external validity. This
0873-2159/$ – see front matter © 2011 Sociedade Portuguesa de Pneumolotaff (a nurse or doctor) to supervise the tests. It would
lso require all patients under consideration for portable
xygen therapy to actually undergo 3 walk tests (4, counting
he practice walk): a walk at baseline, a walk to titrate
xygen ﬂow, and a walk to evaluate response -- this last
ne preferably taking place on a different day from the
rst one.4 In most cases, however, the only test likely to
e performed is the walk to set ﬂow. Third, if oxygen is
o be prescribed for patients who are unable to take the
alk test because of some contraindication (e.g., angina),
he guidelines as they are written will not be followed.5
t present, most patients are receiving AO without a prior
MWT being performed. On the contrary, the public health
uthorities have established the 6MWT as a prerequisite for
he prescription of portable oxygen therapy in an attempt
o reduce the cost of domiciliary respiratory therapies.
inally, as the authors have shown, acute improvement in
MWT parameters was not predictive of enhancement of
utdoor activities with AO. So, what can we do?
We daily see many patients who live more comfortably
nd with less dyspnoea on AO. We do not think proba-
ly that the 6MWT is the best tool to test the beneﬁts
f AO in our patients. Would a simple walk be enough?
2-min walk test? Should we guarantee the use of as
uch oxygen as the patient can take if a chronic respi-
atory insufﬁciency6 is present? The study by Vieira et al.
s of interest for those who prescribe AO in their practice
nd it underscores the need for further study to iden-
ify the type of patient who will truly beneﬁt from such
herapy.
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esponse to the letter ‘‘Ambulatory
xygen: Is the 6 minute walk test
he best option?’’
esposta à carta ‘‘Oxigenoterapia de
eambulac¸ão: será o teste de 6 minutos de
archa a melhor opc¸ão?’’
e would like to thank the authors for their comment on our
rticle1 about the study on the prescription of ambulatory
xygen (AO) and for raising very pertinent and important
ssues.
Our ﬁndings of relatively low adherence to prescribed
O are consistent with other studies, for example, a recent
talian survey2 which conﬁrmed that only 41% of the patients
eported used liquid oxygen when outside the house.
In our study we clearly deﬁned the criteria for use of AO;
hese consisted of exercise hypoxemia which is documented
y a standardized 6-min walk test (6MWT) on air, evidence
f signiﬁcant desaturation (to 88% or less), the patient being
esponsive to oxygen, and signiﬁcant daily activity. Accord-
ng to our data, positive response during the 6MWT did not
elp to predict greater use of the portable oxygen systems
POS). This led us to the conclusion, highlighted in the arti-
le, that non-adherence to AO may be closely related to the
ocial stigma or the physical characteristics (like weight) of
he POS.
The authors correctly discuss the role of the 6MWT in
rescribing AO. In fact, although the ATS statement on the
MWT3 is not very clear in relation to prescribing AO, some
uthors have suggested the need for up to ﬁve 6MWT. To min-
mize the learning effect, the ﬁrst two are training sessions,
ne of which may be performed with the patient carry-
ng the weight of the oxygen source,4 and then the oxygen
itration should be performed after three 6MWT to evaluate
he effect of breathing air and two different oxygen doses.5
owever, there is no standard titration method. According to
he COPD ATS Guidelines it is recommended that the rest-
ng ﬂow rate be increased by 1l/min during exercise.6 We
pted to perform the walk test with the highest ﬂow possible
6 L/min) because in some studies doubling the resting dose
as not sufﬁcient to prevent hypoxemia 4 and we wanted
o make sure of providing adequate oxygenation during all
ctivities. Moreover, we do not believe that in the real world
he repetition of so many 6MWT is actually feasible and, in
act, 26% of respirologists around the world do not perform
should be followed by a review after two months when the
true value of AO can be judged by interview, diary card and
oxygen usage’’. In addition home follow-up within 4 weeks
is strongly recommended. Without this monitoring patients
might use systems or settings that do not maintain adequate
oxygenation and as a consequence their physical activity is
restricted and the health beneﬁts lost. In our centre this
strict protocol is not followed and so long-term compliance
with AO can be affected.
We believe, therefore, that the acute assessment should
be only one component of an AO evaluation. Objective
compliance of oxygen use is urgently needed and newly
designed Oxygen Therapy Monitoring Devices can improve
the management of these patients.9
As we stated (because acute improvements in 6MWT
parameters do not help predict outdoor activities) we need
better tests to identify those who really respond to AO.
As has been suggested by Vonbank et al.10 hemodynamic
response to oxygen can be a better predictor. Others have
implied that the more hyperinﬂated COPD patients are the
ones that can beneﬁt most11 or we may even have to be
more stringent in the criteria for AO prescription as sug-
gested by Leach et al.5 and only consider those who show
50% improvement in exercise ability!
One thing is certain, although we have to increase the
consensus around AO prescription, repeated educational
sessions are deﬁnitely needed to improve compliance to
long-term oxygen therapy.
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